SUMMARY OF SAFETY AND EFFECTIVENESS
Woodside Biomedical Inc. ReliefBand® NST™ Device
Models WB-2, WB-6, and WB-R

K982436

SUBMITTER INFORMATION
A. Company Name: Woodside Biomedical, Inc.
B. Company Address: 1915 Aston Avenue, Suite 102
   Carlsbad, CA 92008
C. Company Phone: (760) 804-6900
   Company Fax: (760) 804-6925
D. Contact Person: Tom Grey
   Vice-President of Product
   Development
   Woodside Biomedical, Inc.
E. Date Summary Prepared: July 7, 1998

DEVICE IDENTIFICATION
A. Generic Device Name: Nerve Stimulation Therapy Device
B. Trade/Proprietary Name: ReliefBand® NST™ (Nerve Stimulation Therapy) Device
C. Classification: Class II
D. Product Code: GZJ and BWK

IDENTIFICATION OF PREDICATE DEVICE

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>510(k) No.</th>
<th>Date Cleared</th>
</tr>
</thead>
<tbody>
<tr>
<td>ReliefBand, Model SW-111</td>
<td>Woodside Biomedical, Inc.</td>
<td>K980333</td>
<td>February 18, 1998</td>
</tr>
</tbody>
</table>
DEVICE DESCRIPTION

The ReliefBand® NST™ Device Models WB-2, WB-6, and WB-R are non-invasive nerve stimulation therapy devices, and are indicated for use in the treatment of nausea and vomiting (NV) due to chemotherapy, motion sickness, pregnancy, and therapy related to acquired immune deficiency syndrome (AIDS). The devices are contained within a wristband, and provide relief of nausea and vomiting through electrical stimulation of the nerves in the patient’s wrist.

The devices can be worn on the ventral or palmar (i.e., inside) surface of either or both wrists, approximately 2 fingers breadth above the distal skin crease of the wrist joint, between the tendons of the palmaris longus and flexor carpi radialis muscles.

The ReliefBand® NST™ Device Models WB-2, WB-6, and WB-R have a single dial for setting the stimulation, and incorporate an LED which is used to display a normal operating condition (green color at a slow flash rate) and a low battery condition (red color at a faster flash rate).

All three models have a single operating mode, controlled by a single dial, which controls the peak pulse amplitude of the electrical impulse and thereby determines the intensity of the stimulation. The three models vary by (1) the number of intensity settings available to the user, (2) whether or not the device is reusable, and (3) the length of time that the batteries will last. These features are summarized in Table 1:

<table>
<thead>
<tr>
<th>Identification of discrete impulse intensity levels</th>
<th>WB-2 (2-Day, Disposable)</th>
<th>WB-6 (6-Day, Disposable)</th>
<th>WB-R (Reusable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1</td>
<td>Level 1</td>
<td>Level 1</td>
<td>Level 1</td>
</tr>
<tr>
<td>Level 2</td>
<td>Level 1.5</td>
<td>Level 2</td>
<td>Level 1.5</td>
</tr>
<tr>
<td>Level 3</td>
<td>Level 2.5</td>
<td>Level 3</td>
<td>Level 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Level 2.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Level 3</td>
</tr>
</tbody>
</table>
The user dial on the WB-2, WB-6, and WB-R devices identifies the intensity level, so the patient can select the desired stimulation easily. All models are powered by two 3V lithium batteries. The batteries in Models WB-2 and WB-6 are not user replaceable. The batteries in Model WB-R are user replaceable and are commercially available. Battery life for the three models is as follows:

- Model WB-2: approximately 2 days (48 hours) on level 2; batteries not replaceable.
- Model WB-6: approximately 6 days (144 hours) on level 2; batteries not replaceable.
- Model WB-R: approximately 6 days (144 hours) on level 2 before the batteries need to be replaced.

SUBSTANTIAL EQUIVALENCE

The Woodside Biomedical, Inc. ReliefBand® NST™ devices, Models WB-2, WB-6, and WB-R devices are of comparable type and are substantially equivalent to the predicate ReliefBand®, Model SW-111 (K980333).

INDICATION FOR USE

The ReliefBand® NST™ Device is indicated for use in the treatment of nausea and vomiting (NV) due to chemotherapy, motion sickness, pregnancy, and therapy related to acquired immune deficiency syndrome (AIDS).

TECHNOLOGICAL CHARACTERISTICS

A comparison of the technological characteristics of the ReliefBand® NST™ Device and the predicate device has been performed. The results of this comparison demonstrate that the ReliefBand® NST™ Device is equivalent to the marketed predicate device.
PERFORMANCE DATA

The performance data indicate that the ReliefBand® NST™ Device Models WB-2, WB-6, and WB-R are substantially equivalent to the ReliefBand® Devices distributed under K980333.
Ms. Carol L. Patterson
Patterson Consulting Group
Consultant for Woodside Biomedical, Inc.
18140 Smokesignal Drive
San Diego, California 92127

Re: K982436
Trade Name: ReliefBand® NST™ Device
    Models WB-2, WB-6, WB-R
Regulatory Class: II
Product Codes: GZJ and BWK
Dated: July 13, 1998
Received: July 14, 1998

Dear Ms. Patterson:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Celia M. Witten, Ph.D., M.D.
Director
Division of General and
Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure
INDICATIONS FOR USE

510(k) Number: K982436

Device Name: ReliefBand® NST™ Device Models WB-2, WB-6, and WB-R

Indications For Use: The ReliefBand® NST™ Device is indicated for use in the treatment of nausea and vomiting (NV) due to chemotherapy, motion sickness, and pregnancy.

PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use [X] OR Over-The-Counter Use [ ]
(Per 21 CFR 801.109)